Dr. Rieko Yajima Announced As New Selection Committee Member For GHIT
Posted on July 31st, 2020
Dr. Rieko Yajima, SPARK’s Director of Drug Discovery Innovation, has been serving as a member of the Selection Committee for the Global Health Innovative Technology (GHIT) Fund since April 2020. The GHIT Fund is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), Japanese pharmaceutical and diagnostics companies, the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world including TB, malaria and neglected tropical diseases. As part of a diverse committee of experts in R&D drug, vaccine and diagnostics development, Dr. Yajima will evaluate investment proposals and reports from development partners and recommend investments to the Board of Directors.
Permalink: https://sparkmed.stanford.edu/dr-rieko-yajima-announced-as-new-selection-committee-member-for-ghit/